Nintedanib
Active ingredient: Nintedanib Esylate
In short: Nintedanib Capsules is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). Nintedanib Capsules is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype .
What is Nintedanib used for?
Nintedanib Capsules is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF).
Nintedanib Capsules is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype .
Nintedanib dosage
Conduct liver function tests in all patients and a pregnancy test in females of reproductive potential prior to initiating treatment with Nintedanib Capsules
.
The recommended dosage of Nintedanib Capsules is 150 mg taken orally twice daily administered approximately 12 hours apart.
Administration Information
Nintedanib Capsules should be taken with food
and swallowed whole with liquid. Nintedanib Capsules should not be chewed because of a bitter taste.
Nintedanib Capsules should not be opened or crushed. If contact with the content of the capsule occurs, wash hands immediately and thoroughly. The effect of chewing or crushing of the capsule on the pharmacokinetics of nintedanib is not known.
Information for Missed Dose
If a dose of Nintedanib Capsules is missed, the next dose should be taken at the next scheduled time. Advise the patient to not make up for a missed dose. Do not exceed the recommended maximum daily dosage of 300 mg.
Mild Hepatic Impairment
In patients with mild hepatic impairment (Child Pugh A), the recommended dosage of Nintedanib Capsules is 100 mg orally twice daily approximately 12 hours apart taken with food
.
Moderate or Severe Hepatic Impairment
Treatment with Nintedanib Capsules is not recommended
.
In addition to symptomatic treatment, if applicable, the management of adverse reactions of Nintedanib Capsules may require dose reduction or temporary interruption until the specific adverse reaction resolves to levels that allow continuation of therapy. Nintedanib Capsules treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If a patient does not tolerate 100 mg twice daily, discontinue treatment with Nintedanib Capsules
.
Elevated Liver Enzymes
Dose modifications or interruptions may be necessary for liver enzyme elevations. Conduct liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin) prior to initiation of treatment with Nintedanib Capsules, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Discontinue Nintedanib Capsules in patients with AST or ALT greater than 3 times the upper limit of normal (ULN) with signs or symptoms of liver injury and for AST or ALT elevations greater than 5 times the upper limit of normal. For AST or ALT greater than 3 times to less than 5 times the ULN without signs of liver damage, interrupt treatment or reduce Nintedanib Capsules to 100 mg twice daily. …
How to take Nintedanib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (
Patient Information).
Elevated Liver Enzymes and Drug-Induced Liver Injury
Advise patients that they will need to undergo liver function testing periodically. Advise patients to immediately report any symptoms of a liver problem (e.g., skin or the whites of eyes turn yellow, urine turns dark or brown (tea colored), pain on the right side of stomach, bleed or bruise more easily than normal, lethargy, loss of appetite)
.
Gastrointestinal Disorders
Inform patients that gastrointestinal disorders such as diarrhea, nausea, and vomiting were the most commonly reported gastrointestinal events occurring in patients who received nintedanib capsules. Advise patients that their healthcare provider may recommend hydration, antidiarrheal medications (e.g., loperamide), or anti-emetic medications to treat these side effects. Temporary dosage reductions or discontinuations may be required. Instruct patients to contact their healthcare provider at the first signs of diarrhea or for any severe or persistent diarrhea, nausea, or vomiting
.
Embryo-Fetal Toxicity
Counsel patients on pregnancy prevention and planning. …
Warnings & precautions
Do not take this medicine if: None
Treatment with Nintedanib Capsules is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment
. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dose of Nintedanib Capsules
.
Cases of drug-induced liver injury (DILI) have been observed with nintedanib capsules treatment. In the clinical trials and postmarketing period, non-serious and serious cases of DILI were reported. Cases of severe liver injury with fatal outcome have been reported in the postmarketing period. The majority of hepatic events occur within the first three months of treatment. In clinical trials, administration of nintedanib capsules was associated with elevations of liver enzymes (ALT, AST, ALKP, GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases. In IPF studies (Study 1, Study 2, and Study 3), the majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), the majority (95%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (94%) of patients with bilirubin elevations had elevations less than 2 times ULN
.
Patients with a low body weight (less than 65 kg), Asian, and female patients may have a higher risk of elevations in liver enzymes. Nintedanib exposure increased with patient age, which may also result in a higher risk of increased liver enzymes
. …
Nintedanib side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Elevated Liver Enzymes and Drug-Induced Liver Injury
Gastrointestinal Disorders
Embryo-Fetal Toxicity
Arterial Thromboembolic Events
Risk of Bleeding
Gastrointestinal Perforation
Nephrotic Range Proteinuria
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of nintedanib capsules was evaluated in over 1000 IPF patients and 332 patients with chronic fibrosing ILDs with a progressive phenotype. Over 200 IPF patients were exposed to nintedanib capsules for more than 2 years in clinical trials.
Idiopathic Pulmonary Fibrosis
Nintedanib capsules were studied in three randomized, double-blind, placebo-controlled, 52-week trials. In the phase 2 (Study 1) and phase 3 (Study 2 and Study 3) trials, 723 patients with IPF received nintedanib capsules 150 mg twice daily and 508 patients received placebo. The median duration of exposure was 10 months for patients treated with nintedanib capsules and 11 months for patients treated with placebo. Subjects ranged in age from 42 to 89 years (median age of 67 years). Most patients were male (79%) and Caucasian (60%). …
Drug interactions
Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4
. Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with Nintedanib Capsules may increase exposure to nintedanib
. In such cases, patients should be monitored closely for tolerability of Nintedanib Capsules. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with Nintedanib Capsules
.
Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John’s wort) with Nintedanib Capsules should be avoided as these drugs may decrease exposure to nintedanib
.
Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary
.
In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone did not alter the exposure of either agent
. …
About this medicine
Nintedanib Capsules contain nintedanib, a kinase inhibitor
. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1
H-Indole-6-carboxylic acid, 2,3-
dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-,methyl ester, (3Z)-, ethanesulfonate (1:1).
Its structural formula is:
Nintedanib esylate is a bright yellow powder with an empirical formula of C31H33N5O4ꞏC2H6O3S and a molecular weight of 649.76 g/mol.
Nintedanib Capsules for oral administration are available in 2 dose strengths containing 100 mg or 150 mg of nintedanib (equivalent to 120.40 mg or 180.60 mg nintedanib ethanesulfonate, respectively). The inactive ingredients of Nintedanib Capsules are the following: Fill Material: Medium-chain triglycerides, lecithin. Capsule Shell: gelatin, glycerin, ferric oxide red, ferric oxide yellow, titanium dioxide, black ink.
How it works: Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4ecf7f05-4a95-b98c-e063-6394a90ab896. Read the full official label on DailyMed.